While pan-HER2 inhibitors did not confirm the expected potential for disease control, novel and more selective HER2 TKIs showed a promising activity in HER2 exon20 insertion mutant pre-treated NSCLC patients. Here, ERBB2 is linked to non-small cell lung carcinoma.